
425 FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPI 1A/1B HCV PATIENTS
G.R. Foster, P. Buggisch, P. Marcellin, S. Zeuzem, K. Agarwal, M. Manns, D. Sereni, H. Klinker, C. Moreno, J.P. Zarski, Y. Horsmans, M. Shelton, S. Arterburn, W. Lee, J. McHutchison, W. Delaney, D. OlVolume:
54
Année:
2011
Langue:
english
DOI:
10.1016/s0168-8278(11)60427-3
Fichier:
PDF, 43 KB
english, 2011